Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1863287 | 1.00 | KMT2A (0.31) | KMT2AEPHX2TP53TSHRHIF1A | |
| SCHEMBL1863195 | 0.79 | KDM5A (0.42) | KMT2ATP53HIF1AHSD17B10LMNA | |
| SCHEMBL1859509 | 0.73 | LMNA (0.40) | KMT2ATP53LMNASMN1; SMN2 | |
| SCHEMBL1864017 | 0.72 | LMNA (0.43) | KMT2ATP53LMNASMN1; SMN2 | |
| SCHEMBL3595030 | 0.70 | TP53 (0.43) | TP53TSHRHIF1AHSD17B10LMNA | |
| SCHEMBL3603989 | 0.70 | TP53 (0.43) | TP53TSHRHIF1AHSD17B10LMNA | |
| SCHEMBL1870675 | 0.68 | TP53 (0.40) | TP53TSHRHIF1AHSD17B10LMNA | |
| SCHEMBL6336425 | 0.68 | EPHX2 (0.39) | EPHX2TP53TSHRLMNASMN1; SMN2 | |
| SCHEMBL5064891 | 0.66 | TP53 (0.44) | KMT2AEPHX2TP53TSHRHIF1A | |
| SCHEMBL6336422 | 0.65 | TP53 (0.38) | TP53TSHRHIF1AHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | DNPEP, PEPD, ACE | KMT2A 2621/4885EPHX2 2718/4885TP53 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.